Genetic deletion of platelet glycoprotein lb alpha but not its extracellular domain protects from atherosclerosis

Thrombosis and Haemostasis

Volumn 112, Issue 6, 2014, Pages 1252-1263

  Koltsova, Ekaterina K ^a,b   Sundd, Prithu ^c   Zarpellon, Alessandro ^d   Ouyang, Hui ^a   Mikulski, Zbigniew ^a   Zampolli, Antonella ^d   Ruggeri, Zaverio M ^d   Ley, Klaus ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aorta; Atherosclerosis; Inflammation; Myeloid cells; Platelets

Indexed keywords

ADHESION RECEPTOR; AUTACOID; CCL5 PROTEIN, MOUSE; CD11B ANTIGEN; GLYCOPROTEIN P 15095; IL12A PROTEIN, MOUSE; INTERLEUKIN 12P35; INTERLEUKIN 4 RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; RANTES; THROMBIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; AORTIC DISEASES; ATHEROSCLEROSIS; BERNARD SOULIER DISEASE; BLOOD; BONE MARROW TRANSPLANTATION; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MONOCYTE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; THROMBOCYTE; THROMBOCYTE ADHESION; WESTERN DIET;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD11C; AORTIC DISEASES; ATHEROSCLEROSIS; BERNARD-SOULIER SYNDROME; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CHEMOKINE CCL5; DIET, WESTERN; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN-12 SUBUNIT P35; LIPOPROTEINS, LDL; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-4; RECEPTORS, LDL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84914159450     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-02-0130     Document Type: Article

References (66)

1. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97–103.
2. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Med 2003; 9: 61–67.
3. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378–3384.
4. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002; 99: 4486–4493.
5. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887–896.
6. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498–511.
7. Sarma J, Laan CA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166–2171.
8. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591–594.
9. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772–1777.
10. Gawaz M, Page S, Massberg S, et al. Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb Haemost 2002; 88: 307–314.
11. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98: 1164–1171.
12. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothe-lial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998; 187: 329–339.
13. Gawaz M, Brand K, Dickfeld T, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75–85.
14. Frenette PS, Johnson RC, Hynes RO, et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450–7454.
15. Frenette PS, Denis CV, Weiss L, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413–1422.
16. Braun OO, Slotta JE, Menger MD, et al. Primary and secondary capture of platelets onto inflamed femoral artery endothelium is dependent on P-selectin and PSGL-1. Eur J Pharmacol 2008; 592: 128–132.
17. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003; 101: 2661–2666.
18. Manka D, Forlow SB, Sanders JM, et al. Critical role of platelet P-selectin in the response to arterial injury in apolipoprotein-E-deficient mice. Arterioscl Thromb Vasc Biol 2004; 24: 1124–1129.
19. Phillips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation 2003; 107: 2244–2249.
20. Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol 2007; 14: 262–269.
21. Andrews RK, Gardiner EE, Shen Y, et al. Glycoprotein Ib-IX-V. Intern J Biochem Cell Biol 2003; 35: 1170–1174.
22. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803–814.
23. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193–204.
24. Wang Y, Sakuma M, Chen Z, et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 2005; 112: 2993–3000.
25. Ghasemzadeh M, Kaplan ZS, Alwis I, et al. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood 2013; 121: 4555–4566.
26. Andrews RK, Berndt MC. Bernard-soulier syndrome: an update. Semin Thromb Hemost 2013; 39: 656–662.
27. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803–2808.
28. Strassel C, Nonne C, Eckly A, et al. Decreased thrombotic tendency in mouse models of the Bernard-Soulier syndrome. Arterioscl Thromb Vasc Biol 2007; 27: 241–247.
29. Kahn ML, Diacovo TG, Bainton DF, et al. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood 1999; 94: 4112–4121.
30. Abdulla A, Awla D, Hartman H, et al. Platelets regulate P-selectin expression and leukocyte rolling in inflamed venules of the pancreas. Eur J Pharmacol 2012; 682: 153–160.
31. Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nature Med 2005; 11: 1167–1169.
32. Hime NJ, Black AS, Bulgrien JJ, et al. Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP. J Lipid Res 2008; 49: 2113–2123.
33. Koltsova EK, Kim G, Lloyd KM, et al. IL-27 Receptor Limits Atherosclerosis in Ldlr-/- Mice. Circulation Res 2012; 111: 1274-1285.
34. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood 2002; 100: 2102–2107.
35. Koltsova EK, Garcia Z, Chodaczek G, et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest 2012; 122: 3114–3126.
36. Sundd P, Gutierrez E, Pospieszalska MK, et al. Quantitative dynamic footprinting microscopy reveals mechanisms of neutrophil rolling. Nature Meth 2010; 7: 821–824.
37. Sundd P, Gutierrez E, Koltsova EK, et al.‘Slings’ enable neutrophil rolling at high shear. Nature 2012; 488: 399–403.
38. Sundd P, Gutierrez E, Petrich BG, et al. Live cell imaging of paxillin in rolling neutrophils by dual-color quantitative dynamic footprinting. Microcirculation 2011; 18: 361–372.
39. Chiang EY, Hidalgo A, Chang J, et al. Imaging receptor microdomains on leukocyte subsets in live mice. Nature Meth 2007; 4: 219–222.
40. Sumagin R, Prizant H, Lomakina E, et al. LFA-1 and Mac-1 define characteristically different intralumenal crawling and emigration patterns for monocytes and neutrophils in situ. J Immunol 2010; 185: 7057–7066.
41. An G, Wang H, Tang R, et al. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 2008; 117: 3227–3237.
42. Tasaka S, Richer SE, Mizgerd JP, et al. Very late antigen-4 in CD18-independent neutrophil emigration during acute bacterial pneumonia in mice. Am J Resp Crit Care Med 2002; 166: 53–60.
43. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009; 29: 1419–1423.
44. Rautou PE, Vion AC, Amabile N, et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593–606.
45. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77–86.
46. Simon DI, Zidar D. Neutrophils in atherosclerosis: alarmin evidence of a hit and run? Circulation Res 2012; 110: 1036–1038.
47. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130–2132.
48. Vintersten K, Monetti C, Gertsenstein M, et al. Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult animals. Genesis 2004; 40: 241–246.
49. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71–82.
50. Knight CJ. Antiplatelet treatment in stable coronary artery disease. Heart 2003; 89: 1273–1278.
51. Massberg S, Schurzinger K, Lorenz M, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005; 112: 1180–1188.
52. Fujimura Y, Titani K, Holland LZ, et al. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381–385.
53. Ruggeri ZM, Zarpellon A, Roberts JR, et al. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb Haemost 2010; 104: 894–902.
54. Methia N, Andre P, Denis CV, et al. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98: 1424–1428.
55. Zarpellon A, Celikel R, Roberts JR, et al. Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib (alpha) sulfotyrosines through a two-site mechanism involving exosite I. Proc Natl Acad Sci USA 2011; 108: 8628–8633.
56. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746–1760.
57. Ruggeri ZM, De Marco L, Gatti L, et al. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 1983; 72: 1–12.
58. Dejana E, Lampugnani MG, Giorgi M, et al. Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism. J Cell Biol 1989; 109: 367–375.
59. Wolf D, Hohmann JD, Wiedemann A, et al. Binding of CD40L to Mac-1’s I-do-main involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. Circulation Res 2011; 109: 1269–1279.
60. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nature Med 2002; 8: 247–252.
61. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690–694.
62. Cranmer SL, Ashworth KJ, Yao Y, et al. High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbalpha-filamin interaction. Blood 2011; 117: 2718–2727.
63. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscl Thromb Vasc Biol 2011; 31: 1506–1516.
64. Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50– to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425–434.
65. Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358–2368.
66. Strassel C, Hechler B, Bull A, et al. Studies of mice lacking the GPIb-V-IX complex question the role of this receptor in atherosclerosis. J Thromb Haemost 2009; 7: 1935–1938.